Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 10/20 | 0.38 |
| ▸ | MMP3 | P08254 | 8/20 | 0.38 |
| ▸ | MMP13 | P45452 | 8/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.38 |
| ▸ | MMP7 | P09237 | 7/20 | 0.38 |
| ▸ | MMP9 | P14780 | 7/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442982 | 1.00 | MMP12 (0.41) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL6444798 | 0.82 | ALDH1A1 (0.46) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL6444760 | 0.82 | ALDH1A1 (0.46) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL13409570 | 0.78 | MAPT (0.50) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7268612 | 0.78 | MMP12 (0.39) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL7268606 | 0.78 | MMP12 (0.39) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL7920915 | 0.76 | POLB (0.37) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL13591209 | 0.76 | MEN1 (0.52) | MMP12KDM4EMMP2MMP3MMP13 | |
| SCHEMBL3309795 | 0.75 | MMP12 (0.43) | MMP12MMP2MMP3MMP13MMP1 | |
| SCHEMBL3309784 | 0.75 | MMP12 (0.43) | MMP12MMP2MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | MMP12 180/4885KDM4E 3396/4885MMP2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.